He Jiankui affair

He Jiankui affair
The He Lab · CC BY 3.0 · source
Name	He Jiankui affair

He Jiankui affair.

The incident involving He Jiankui attracted global attention when reports emerged that a Chinese scientist had used CRISPR-Cas9 genome editing to modify human embryos that resulted in live births, prompting urgent debate across bioethics, medical research, and international law communities. The revelation intersected with institutions such as Southern University of Science and Technology, regulatory bodies including the National Health Commission (China), and international organizations like the World Health Organization and the International Commission on the Clinical Use of Human Germline Genome Editing. The case provoked responses from research funders, academic publishers, and national legislatures, and sparked widespread discussion in media outlets such as Nature (journal), Science (journal), and the New York Times.

Background

He Jiankui was a scientist affiliated with Southern University of Science and Technology and previously associated with institutions including Rice University, Stanford University, and collaborations with researchers at University of Science and Technology of China. His work drew on techniques developed by laboratories such as those of Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and groups at the Broad Institute and the University of California, Berkeley. Prior discussions about human embryo editing featured debates at forums including the International Summit on Human Gene Editing, with positions advanced by commissions from bodies like the National Academies of Sciences, Engineering, and Medicine and the Nuffield Council on Bioethics.

CRISPR and scientific context

The scientific foundation for the affair rested on CRISPR-Cas9 technology, a genome-editing platform refined by teams including Doudna and Charpentier (winners of the Nobel Prize in Chemistry), and parallel development by Feng Zhang at the Broad Institute. Related editing modalities cited in the literature included base editing proposed by researchers such as David R. Liu at the Broad Institute and prime editing described by the Broad Institute and MIT collaborators. Precedent studies on human embryos were published by laboratories at University of Pennsylvania, Shoukhrat Mitalipov's team at Oregon Health & Science University, and groups in China, prompting commentary from regulators like the U.S. Food and Drug Administration and advisory bodies including the WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing.

The experiment and announcement

In November 2018 reports emerged that He Jiankui had edited the CCR5 gene in embryos used in in vitro fertilization procedures, producing live births reported as twin girls and later claims of a third child. The announcement, made via a YouTube video and in presentations tied to conferences, followed preprints and disclosures that drew scrutiny from journals such as Nature, Science, and Cell. The work cited clinical partners and fertility clinics, and implicated ethical review processes connected to institutional review boards at Southern University of Science and Technology and hospitals in Shenzhen and Guangdong. International responses referenced prior guidance from the International Summit on Human Gene Editing and statements from scientists including George Church, Francis Collins, and Paul Berg.

Ethical, legal, and biosafety concerns

The case raised ethical objections from bodies including the Chinese Academy of Medical Sciences, the World Medical Association, the American Society of Human Genetics, and the European Society of Human Reproduction and Embryology. Concerns focused on clinical trial registration, informed consent documents, risk–benefit assessments, and long-term follow-up obligations under guidelines from the Declaration of Helsinki and oversight frameworks endorsed by the Council for International Organizations of Medical Sciences. Biosafety organizations such as the Centers for Disease Control and Prevention and policy groups like the Council of Europe's bioethics committees referenced potential off-target effects documented in studies from the Salk Institute and others, and highlighted implications under national laws including provisions of the Criminal Law of the People's Republic of China and regulations from the National Health Commission (China).

Investigations, trials, and sanctions

Chinese authorities including the National Health Commission (China) and provincial health commissions conducted investigations, leading to disciplinary actions, the shutdown of associated labs, and criminal prosecutions. Courts and disciplinary bodies cited violations of regulations on assisted reproductive technology and clinical trial oversight, invoking statutes under the Criminal Law of the People's Republic of China. International academic repercussions included retractions, bans from conference participation, and institutional investigations at universities such as Southern University of Science and Technology, Stanford University, and Rice University. The case prompted parliamentary inquiries in jurisdictions including the United States Congress and legislative attention in the European Parliament.

Public reaction and policy impact

Public and professional reactions spanned commentary from scientists including Jennifer Doudna, Emmanuelle Charpentier, George Daley, and Leah Jamieson, statements from organizations like the World Health Organization that convened expert panels, and policy shifts in national agencies such as the U.S. National Institutes of Health and the UK Human Fertilisation and Embryology Authority. Media coverage by outlets including the BBC, CNN, The Guardian, and The Washington Post shaped public debate. In response, several countries updated statutes or guidance on germline editing, and funding agencies such as the Wellcome Trust and the Howard Hughes Medical Institute issued policy statements reinforcing research ethics and oversight.

Legacy and ongoing debates

The affair intensified discussions about moratoria, governance frameworks like those proposed by the International Commission on the Clinical Use of Human Germline Genome Editing, and proposals for registries similar to those advocated by the World Health Organization. Scientific debates continued about technical improvements from teams led by David R. Liu, Feng Zhang, and others, on reducing off-target edits and improving delivery systems explored at institutions like the Broad Institute, MIT, and Harvard University. Ethical discourse persisted in forums hosted by the Nuffield Council on Bioethics, the National Academies, and international consortia, while legal scholars referenced comparative law analyses involving the European Court of Human Rights and national constitutional frameworks. The episode remains a focal point in discussions about translational limits, researcher responsibility, and global coordination among bodies such as the World Health Organization and national regulators.

Category:Bioethics Category:Gene editing Category:Human subject research